

Clinical Guideline

Chronic Pain: Narcotic Treatment Eligibility

Non-Narcotic Analgesics on the YKHC Formulary

Muscle Relaxants

- Baclofen
- Cyclobenzaprine
- Tizanidine

NSAIDS

- Aspirin
- Ibuprofen
- Indomethacin
- Meloxicam
- Nabumetone
- Naproxen

Topical Analgesics

- Capsaicin Cream
- · Diclofenac gel
- Lidocaine patch
- Lidocaine topical jelly
- Mentholmethylsalicicylate (BenGay)

Other

Acetaminophen

SNRI

Duloxetine

Tricyclics


- Amitriptyline
- Nortriptyline

Neuropathic Pain Agents

- Carbamazepine
- Gabapentin
- Pregabalin

Headache Agents

- Butalbital/APAP/Caffeine (Fioricet)
- Rizaltriptan
- Sumatriptan
- Topiramate



Follow-up at least Q6 months. See next page.

Types of Pain and Recommended Management
Treatment options for all types of pain: sleep hygiene, yoga, meditation

Nociceptive Pain (muscle, joint, or visceral): examples include strain, tension headache, osteoarthritis, low back pain, chronic cystitis, myofascial pain. Suggested treatments: NSAIDs, acetaminophen, PT, trigger point or joint injections, capsaicin cream, lidocaine patch/cream, yoga, meditation 2. Neuropathic Pain:

Suggested treatments: NSAIDs, antidepressants (first-line TCAs, duloxetine), gabapentin

Management for specific conditions:

- Nerve compression: EMG, MRI, referral to surgeon
- Nerve damage: EMG
- Nerve traction: EMG, PT, yoga, meditation
- Migraine: sumatriptan, rizatriptan, beta-blockers, etc.
- Reflex sympathetic dystrophy: lidocaine patch
- 3. Idiopathic Pain: examples include fibromyalgia

Suggested treatments: exercise, antidepressants (including duloxetine), yoga, meditation, sleep hygiene


This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner.

Approved by MSEC 2/1/22.

If comments about this guideline, please contact Heidi_Salisbury@ykhc.org.



Clinical Guideline Follow-up of Chronic Pain Patients



For terminal cancer patients (with life expectancy less than or equal to 6 months) who have previously demonstrated good compliance with Chronic Medication agreement, documentation of titration for pain control as appropriate is acceptable without requiring new agreement. Continue to monitor for achievement of goals/behaviors of concern.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner.

Approved by MSEC 2/1/22.

If comments about this guideline, please contact Heidi_Salisbury@ykhc.org.